BioXcel Therapeutics, Inc. (BTAI)
Company Description
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia.
In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.
The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 8, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 183 |
| CEO | Dr. Vimal D. Mehta Ph.D. |
Contact Details
Address:
555 Long Wharf Drive New Haven, Connecticut 06511 United States | |
| Phone | 203-643-8060 |
| Website | bioxceltherapeutics.com |
Stock Details
| Ticker Symbol | BTAI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001720893 |
| CUSIP Number | 09075P105 |
| ISIN Number | US09075P1057 |
| Employer ID | 82-1386754 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vimal D. Mehta Ph.D. | Founder, Chief Executive Officer, President, and Director |
| Dr. Frank D. Yocca Ph.D. | Senior Vice President and Chief Scientific Officer |
| Javier Rodriguez | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Dr. Krishnan Nandabalan Ph.D. | Chief Digital Officer ?& Director |
| Richard I. Steinhart MBA | Senior Vice President and Chief Financial Officer |
| Mary Coleman | Vice President of Investment Relations |
| Dr. Iris Francesconi Ph.D. | Senior Vice President of Marketing, Market Research and Commercial Assessments |
| Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P. | Senior Vice President and Chief Medical Officer |
| Dr. Cedric Burg | Vice President and Head of Global Clinical Operations and Project Management |
| Dr. Chetan D. Lathia Ph.D. | Senior Vice President and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 22, 2023 | 144 | Filing |
| May 17, 2023 | DEF 14A | Other definitive proxy statements |
| May 16, 2023 | 144/A | Filing |
| May 15, 2023 | 144 | Filing |
| May 15, 2023 | 144 | Filing |
| May 9, 2023 | 10-Q | Quarterly Report |
| May 8, 2023 | 8-K | Current Report |
| May 1, 2023 | 10-K/A | [Amend] Annual report |
| Apr 20, 2023 | 8-K | Current Report |
| Apr 4, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |